Apomorphine Sublingual Film + Placebo
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Restless Legs Syndrome
Conditions
Restless Legs Syndrome
Trial Timeline
Sep 1, 2022 → Mar 1, 2023
NCT ID
NCT05529095About Apomorphine Sublingual Film + Placebo
Apomorphine Sublingual Film + Placebo is a approved stage product being developed by Sumitomo Pharma for Restless Legs Syndrome. The current trial status is unknown. This product is registered under clinical trial identifier NCT05529095. Target conditions include Restless Legs Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05529095 | Approved | UNKNOWN |
Competing Products
20 competing products in Restless Legs Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gabapentin enacarbil | Astellas Pharma | Approved | 85 |
| ASP8825 | Astellas Pharma | Phase 3 | 77 |
| Regnite | Astellas Pharma | Pre-clinical | 23 |
| ASP8825 + Placebo | Astellas Pharma | Phase 2 | 52 |
| Placebo + Gabapentin enacarbil | Astellas Pharma | Approved | 85 |
| Suvorexant | Merck | Approved | 85 |
| Cabergoline | Pfizer | Phase 3 | 76 |
| Placebo + pregabalin + pregabalin | Pfizer | Phase 3 | 76 |
| placebo + Pregabalin + Pregabalin + Pregabalin + Pregabalin + Pregabalin | Pfizer | Phase 2 | 51 |
| pregabalin + placebo + pramipexole | Pfizer | Phase 3 | 76 |
| placebo and pregabalin + pramipexol + pramipexol + Pregabalin + pramipexol + pramipexol | Pfizer | Phase 3 | 76 |
| cabergoline + levodopa | Pfizer | Phase 3 | 76 |
| Rotigotine | UCB | Phase 3 | 74 |
| Neupro® | UCB | Pre-clinical | 20 |
| Rotigotine Nasal Spray | UCB | Phase 2 | 49 |
| Rotigotine | UCB | Phase 3 | 74 |
| Levetiracetam (Keppra) | UCB | Phase 2 | 49 |
| Rotigotine + Placebo | UCB | Approved | 82 |
| Rotigotine | UCB | Phase 2 | 49 |
| Rotigotine | UCB | Phase 3 | 74 |